Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 61-67

  Kijima, Noriyuki ^a   Hosen, Naoki ^a   Kagawa, Naoki ^a   Hashimoto, Naoya ^a   Kinoshita, Manabu ^a   Oji, Yusuke ^a   Sugiyama, Haruo ^a   Yoshimine, Toshiki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Glioblastoma; Tumorigenicity; WT1

Indexed keywords

PEPTIDE VACCINE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; WILMS TUMOR 1 PEPTIDE VACCINE; DNA BINDING PROTEIN; RAG2 PROTEIN, MOUSE; SMALL INTERFERING RNA; TUMOR MARKER; WT1 PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; SCID MOUSE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR XENOGRAFT; ANIMAL; DNA MICROARRAY; DRUG ANTAGONISM; DRUG SCREENING; ENZYME IMMUNOASSAY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; SURVIVAL RATE; TUMOR CELL CULTURE; WT1;

APOPTOSIS; GLIOBLASTOMA; TUMORIGENICITY; WT1;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897020240     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus comcomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987-996, 2005.
2. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H and Yoshimine T: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108(5): 963-971, 2008.
3. Oji Y, Inohara H, Nakazawa M, Nakano Y, Akahani S, Nakatsuka S, Koga S, Ikeba A, Abeno S, Honjo Y, Yamamoto Y, Iwai S, Yoshida K, Oka Y, Ogawa H, Yoshida J, Aozasa K, Kubo T and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 94(6): 523-529, 2003.
4. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, Yao M, Takahashi E, Nakano Y, Hirabayashi H, Shintani Y, Oka Y, Tsuboi A, Hosen N, Asada M, Fujioka T, Murakami M, Kanato K, Motomura M, Kim EH, Kawakami M, Ikegame K, Ogawa H, Aozasa K, Kawase I and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100(3): 297-303, 2002.
5. Oji Y, Miyoshi Y, Koga S, Nakano Y, Ando A, Nakatsuka S, Ikeba A, Takahashi E, Sakaguchi N, Yokota A, Hosen N, Ikegame K, Kawakami M, Tsuboi A, Oka Y, Ogawa H, Aozasa K, Noguchi S and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Cancer Sci 94(7): 606-611, 2003.
6. Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, Abeno S, Ikeba A, Takashima S, Tsujie M, Yamamoto H, Sakon M, Nezu R, Kawano K, Nishida S, Ikegame K, Kawakami M, Tsuboi A, Oka Y, Yoshikawa K, Aozasa K, Monden M and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 95(7): 583-587, 2004.
7. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, Abeno S, Tatsumi N, Yokota A, Aoyagi S, Nakazawa T, Ito K, Kanato K, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Aozasa K, Yoshimine T and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Sci 95(10): 822-827, 2004.
8. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, Abeno S, Kiyotoh E, Jomgeow T, Sekimoto M, Nezu R, Yoshikawa Y, Inoue Y, Hosen N, Kawakami M, Tsuboi A, Oka Y, Ogawa H, Souda S, Aozasa K, Monden M and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 94(8): 712-717, 2003.
9. Oji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, Yasuda T, Fujiwara Y, Takiguchi S, Yamamoto H, Fujita S, Kanato K, Ito K, Jomgeow T, Kawakami M, Tsuboi A, Shirakata T, Nishida S, Hosen N, Oka Y, Aozasa K, Monden M and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res 24(5B): 3103-3108, 2004.
10. Ueda T, Oji Y, Naka N, Nakano Y, Takahashi E, Koga S, Asada M, Ikeba A, Nakatsuka S, Abeno S, Hosen N, Tomita Y, Aozasa K, Tamai N, Myoui A, Yoshikawa H and Sugiyama H: Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 94(3): 271-276, 2003.
11. Clark AJ, Dos Santos WG, McCready J, Chen MY, Van Meter TE, Ware JL, Wolber SB, Fillmore H and Broaddus WC: Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. J Neurosurg 107(3): 586-592, 2007.
12. Coppes MJ, Campbell CE and Williams BR: The role of WT1 in Wilms tumorigenesis. FASEB J 7(10): 886-895, 1993.
13. Rauscher. The WT1 Wilms tumor gene product: A developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J 7(10): 896-903, 1993.
14. Haber DA, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, Sens DA and Garvin AJ: WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science 262(5142): 2057-2059, 1993.
15. Algar EM, Kenney MT, Simms LA, Smith SI, Kida Y and Smith PJ: Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms' tumour associated with high levels of expression of a truncated transcript. Hum Mutat 5(3): 221-227, 1995.
16. Little M and Wells C: A clinical overview of WT1 gene mutations. Hum Mutat 9(3): 209-225 1997.
17. Loeb DM and Sukumar S: The role of WT1 in oncogenesis: tumor suppressor or oncogene? Int J Hematol 76(2): 117-126, 2002.
18. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ and Smith PJ: A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 12(5): 1005-1014, 1996.
19. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A and Maekawa T: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87(7): 2878-2884, 1996.
20. Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, Aoyagi S, Fukuda I, Ito K, Nakamura J, Takashima S, Kitamura Y, Miyai S, Jomgeow T, Li Z, Shirakata T, Nishida S, Tsuboi A, Oka Y and Sugiyama H: Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol 32(3): 701-711, 2008.
21. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Akiyama T, Kishimoto T and Sugiyama H: Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91(8): 2969-2976, 1998.
22. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y, Kim EH, Soma T, Tatekawa T, Kawakami M, Kishimoto T and Sugiyama H: Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 23(5): 499-505 1999.
23. Li H, Oka Y, Tsuboi A, Yamagami T, Miyazaki T, Yusa S, Kawasaki K, Kishimoto Y, Asada M, Nakajima H, Kanato K, Nishida S, Masuda T, Murakami M, Hosen N, Kawakami M, Ogawa H, Melchers F, Kawase I, Oji Y and Sugiyama H: The LCK promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells. Int J Hematol 77(5): 463-470, 2003.
24. Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, Nakazawa T, Tatsumi N, Sakaguchi N, Takashima S, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Itoh K and Sugiyama H: Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 97(4): 259-270, 2006.
25. Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T, Asada M, Jomgeow T, Aoyagi S, Nakano Y, Tamaki H, Sakaguchi N, Shirakata T, Nishida S, Kawakami M, Tsuboi A, Oka Y, Tsujimoto Y and Sugiyama H: Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 25(30): 4217-4229, 2006.
26. Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, Hoshida Y, Nakazawa T, Harada Y, Tatsumi N, Tsuboi A, Kawakami M, Oka Y, Oji Y, Aozasa K, Kawase I, and Sugiyama H. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 107(8): 3303-3312, 2006.
27. Clark AJ, Chan DC, Chen MY, Fillmore H, Dos Santos WG, Van Meter TE, Graf MR and Broaddus WC: Down-regulation of Wilms' tumor 1 expression in glioblastoma cells increases radiosensitivity independently of p53. J Neurooncol 83(2): 163-172, 2007.
28. Clark AJ, Ware JL, Chen MY, Graf MR, Van Meter TE, Dos Santos WG, Fillmore HL and Broaddus WC: Effect of WT1 gene silencing on the tumorigenicity of human glioblastoma multiforme cells. J Neurosurg 112(1): 18-25, 2010.
29. Chidambaram A, Fillmore HL, Van Meter TE, Dumur CI and Broaddus WC: Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness. J Neurosurg 116(4): 843-853, 2012.
30. Chiba Y, Hashimoto N, Tsuboi A, Rabo C, Oka Y, Kinoshita M, Kagawa N, Oji Y, Sugiyama H and Yoshimine T: Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumor Pathol 27(1): 29-34, 2010.